文献速递食管与纵隔外科

临床T2N0食管癌直接食管切除术与诱导放化疗后手术的比较有效性:一项决策分析

Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-01-12

该决策分析比较临床T2N0食管癌直接食管切除术与诱导放化疗后食管切除术的总生存,基线模型中位生存分别为48.3个月与45.9个月。敏感性分析显示当病理升期概率>48.1%时诱导放化疗更优,而肿瘤>3cm、高级别或淋巴血管侵犯任一高危因素与>48.1%升期风险相关。

要点

  • 基线模型两种策略中位生存相近:直接手术48.3个月 vs 诱导放化疗后手术45.9个月。
  • 病理升期概率>48.1%时诱导放化疗带来生存获益,该阈值在已发表的32%至65%升期概率范围内。
  • 肿瘤>3cm、高级别或淋巴血管侵犯任一因素与>48.1%升期风险相关,使诱导放化疗具生存优势。

核心结论

  • cT2N0食管癌的最佳治疗策略取决于内镜超声分期的准确性;具有升期概率增加的高危特征可指导临床决策,以对部分cT2N0患者推荐诱导放化疗。

研究设计与样本

  • 决策分析模型,代表cT2N0食管癌的两种治疗策略:直接食管切除术(升期患者可能后续接受辅助治疗)与所有cT2N0患者接受诱导放化疗后食管切除术。
  • 模型参数值取自已发表数据,病理亚组的中位生存来自美国国家癌症数据库(National Cancer Database)。
  • 敏感性分析通过改变病理升期概率引入内镜超声的分期不确定性。

主要发现

  • 基线模型显示两种策略中位生存相近:直接食管切除术48.3个月 vs 诱导放化疗后手术45.9个月。
  • 敏感性分析显示当升期概率>48.1%时诱导放化疗有益,该阈值处于已发表的cT2N0诊断后病理升期概率32%至65%范围内。
  • 肿瘤大小>3cm、高级别或淋巴血管侵犯这3个关键变量中任一存在,与>48.1%的升期风险相关,从而赋予诱导放化疗生存优势。

关键数值与推荐

  • 病理升期概率>48.1%时诱导放化疗更优。
  • 已发表的cT2N0诊断后病理升期概率范围为32%至65%。
  • 肿瘤>3cm、高级别或淋巴血管侵犯任一高危因素与>48.1%升期风险相关。

临床怎么用

  • 作者认为具有升期概率增加的高危特征可指导临床决策,以对部分cT2N0患者推荐诱导放化疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We compared the effectiveness of upfront esophagectomy versus induction chemoradiation followed by esophagectomy for overall survival in patients with clinical T2N0 (cT2N0) esophageal cancer. We also assessed the influence of the diagnostic uncertainty of endoscopic ultrasound on the expected benefit of chemoradiation. METHODS: We created a decision analysis model representing 2 treatment strategies for cT2N0 esophageal cancer: upfront esophagectomy that may be followed by adjuvant therapy for upstaged patients and induction chemoradiation for all patients with cT2N0 esophageal cancer followed by esophagectomy. Parameter values within the model were obtained from published data, and median survival for pathologic subgroups was derived from the National Cancer Database. In sensitivity analyses, staging uncertainty of endoscopic ultrasound was introduced by varying the probability of pathologic upstaging. RESULTS: The baseline model showed comparable median survival for both strategies: 48.3 months for upfront esophagectomy versus 45.9 months for induction chemoradiation and surgery. The sensitivity analysis demonstrated induction chemoradiation was beneficial, with probability of upstaging > 48.1%, which is within the published range of 32% to 65% probability of pathologic upstaging after cT2N0 diagnosis. The presence of any of 3 key variables (size larger than 3 cm, high grade, or lymphovascular invasion) was associated with > 48.1% risk of upstaging, thus conferring a survival advantage to induction chemoradiation. CONCLUSIONS: The optimal treatment strategy for cT2N0 esophageal cancer depends on the accuracy of endoscopic ultrasound staging. High-risk features that confer increased probability of upstaging can inform clinical decision making to recommend induction chemoradiation for select cT2N0 patients.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Semenkovich TR, Panni RZ, Hudson JL, et al. Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis. J Thorac Cardiovasc Surg. 2018. PMID: 29428700. doi:10.1016/j.jtcvs.2018.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。